BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 , in Chicago, Illinois . Poster... Read More

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 BOULDER, Colo. , Mar. 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the... Read More

BOULDER, Colo. , Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 , at 10:30 a.m. ET . The fireside chat will be... Read More

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose reductions Continued to progress ELVN-002 with a focus on recently initiated combination clinical trials evaluating patients with HER2+ MBC and CRC Strong balance sheet with $292 million in cash, cash equivalents and marketable... Read More

BOULDER, Colo. , Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024 , at 9:30 a.m. GMT . The fireside chat will be webcast... Read More

Updated Phase 1 data presented at ESH-iCMLf 26 th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 remains well-tolerated with no dose reductions reported with 39 patients enrolled and a median treatment duration of 20 weeks at... Read More

BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the updated ELVN-001 Phase 1a data, which was selected for an oral presentation at the upcoming European Society of Hematology International... Read More

Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in the Phase 1a clinical trial evaluating ELVN-002 in combination with trastuzumab +/- chemotherapeutic agents in HER2+ MBC and CRC Strong balance sheet with $312 million in cash, cash equivalents and marketable securities, which is... Read More

BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June: Jefferies Global Healthcare Conference Format: Fireside Chat Date: Wednesday, June 5 Time: 8:30... Read More

Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the... Read More

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative MMR rate of 44% (4/9) by 12 weeks in response-evaluable patients who were previously treated with asciminib ELVN-001 was well tolerated with no ≥ Grade 3 treatment-related non-hematologic toxicities reported Company to host... Read More

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug... Read More

BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid... Read More

Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 and through multiple key clinical milestones for ELVN-001 and ELVN-002 Company to host an event with KOLs on April 11, 2024, to discuss initial proof of concept data from a Phase 1a trial evaluating ELVN-001 in adults with... Read More

Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024 IND application to evaluate ELVN-002 in combination with trastuzumab in patients with HER2+ metastatic breast cancer and colorectal cancer received U.S. FDA clearance Strong balance sheet, closing the year with $253 million in cash, cash equivalents and marketable... Read More

BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference in Boston, MA, on Tuesday, March 5, 2024, at 12:50 p.m. ET. The panel will... Read More

Company on track to deliver initial proof of concept data for ELVN-001 and ELVN-002 in 2024 Strong balance sheet, closing the quarter with $263 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into early 2026 BOULDER, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the... Read More

Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024 Strong balance sheet, closing the quarter with $278 million in cash, cash equivalents and marketable securities BOULDER, Colo., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision... Read More

BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June: Jefferies Healthcare Conference Format: Podium Presentation Date: Thursday, June 8, 2023 Time:... Read More

Successfully completed merger with Imara Inc., trading under the new ticker symbol on Nasdaq, “ELVN” Dosed first patient in Phase 1 study of ELVN-002 in patients with HER2-altered non-small cell lung cancer (NSCLC) and other solid tumors Enrollment progressing in Phase 1 trial with ELVN-001 in chronic myeloid leukemia (CML) Ended the first quarter 2023 with cash and cash equivalents of approximately $292 million, which is... Read More